Abstract:1550 Background: Immune checkpoint blockades (ICBs) have drastically improved the clinical outcomes of cancer patients, while only ~30% of them get significant benefits from immunotherapy. TMB, PD-L1, TNB, GEP (Cristescu et al. 2018) and other conventional biomarkers can explain only ~60% of the ICB response, suggesting that novel factors are yet to be discovered. Methods: Gene expression profiles and clinical information of 672 patients were collected from IMvigor210 (n=348, bladder cancer), Pender et al. (n=98, 20 tumor types), Kim et al. (n=45, gastric cancer) and CheckMate (n=181, kidney cancer) cohorts, in which all patients were treated with ICBs. In each sample, gene expression intensities normalized by RPKM were ranked in descender order (range of 1-20000) and scaled into the 0-1 range lastly. To identify immune signatures that correlated with both response and survival, 1000+ immune genes were downloaded from InnatDB database, and their expression values were compared between the two groups of IMvigor210 data which were divided according to response (CR+PR vs. SD+PD, Wilcoxon test) or overall survival (≥mOS vs. <mOS, Cox survival analysis). Bayesian-regularization neural networks (BRNN) model was used to develop the risk model to predict ICB response and prognosis. 75% of IMvigor210 data were randomly selected as the training set, and the remaining 25% as the test set. The performance of predictor was independently validated in Pender et al., Kim et al., and CheckMate cohorts subsequently. ROC curves were used to evaluate the predictive accuracy to response. Survival plots were created using the Kaplan-Meier estimator, and data were analyzed by log-rank test. Results: 40 DEGs (including top20 DEGs positively correlated with ORR/OS and top20 DEGs negatively correlated with ORR/OS) were identified as immune signatures, in which each gene signature could significantly distinguish ICB response and survival. Our model outperformed TMB or GEP in the prediction of response in IMvigor210 (Model = 0.986 vs. TMB = 0.728 vs. GEP = 0.551), Pender et al. (Model = 0.757 vs. TMB = 0.593 vs. GEP = 0.621), Kim et al. (Model = 0.881 vs. GEP = 0.828), and CheckMate (Model = 0.927 vs. TMB = 0.543) cohorts when AUC was used as performance metric. Meanwhile, our model showed promising results for differentiating longer survivors from shorter survivors with p vale <0.0001, 0.064, 0.021, and 0.0006 in IMvigor210, Pender et al., Kim et al., and CheckMate cohorts respectively. Conclusions: We proposed a deep learning model to predict ICB response and survival, in which feature selection based on immune gene expression order, allowing all kinds of platforms and expression data types. Our model showed a robust prediction not only in bladder cancer, but also in other pan-cancer types.

A Transformer-Based Approach to Survival Outcome Prediction

TransSurv: Transformer-Based Survival Analysis Model Integrating Histopathological Images and Genomic Data for Colorectal Cancer.

Predicting Tissue of Origin from Bulk Tumor Gene Expression using a Pre-trained Transformer Model

An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients

Comprehensive Multimodal Deep Learning Survival Prediction Enabled by a Transformer Architecture: A Multicenter Study in Glioblastoma

Toward Precision Breast Cancer Survival Prediction Utilizing Combined Whole Genome-Wide Expression and Somatic Mutation Analysis

Pathology-and-genomics Multimodal Transformer for Survival Outcome Prediction

Toward the precision breast cancer survival prediction utilizing combined whole genome-wide expression and somatic mutation analysis

Early Stage NSCLS Patients’ Prognostic Prediction with Multi-Information Using Transformer and Graph Neural Network Model

Survival Prediction Across Diverse Cancer Types Using Neural Networks

Transformer As a Spatially Aware Multi-instance Learning Framework to Predict the Risk of Death for Early-stage Non-small Cell Lung Cancer

Gene expression-based machine learning approach to predict immunotherapy response and survival in patients with advanced cancer.

Gene Expression based Survival Prediction for Cancer Patients: A Topic Modeling Approach

Deep learning-based cancer survival prognosis from RNA-seq data: approaches and evaluations

Learning Genomic Representations to Predict Clinical Outcomes in Cancer

BulkRNABert: Cancer prognosis from bulk RNA-seq based language models

Strategies to integrate multi-omics data for patient survival prediction

scSurv: a deep generative model for single-cell survival analysis

A Hybrid CNN-Transformer Model for Predicting N Staging and Survival in Non-Small Cell Lung Cancer Patients Based on CT-Scan

Multimodal Integration of Longitudinal Noninvasive Diagnostics for Survival Prediction in Immunotherapy Using Deep Learning